This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
by Ekta Bagri
NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.
ADMAPositive Net Change NTLAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Eli Lilly to Expand Vaccine Pipeline With Three Biotech Buyouts
by Zacks Equity Research
LLY plans $3.83B in biotech buyouts to expand into vaccines and infectious diseases beyond obesity and diabetes.
SNYNegative Net Change BMYNegative Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?
by Zacks Equity Research
ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.
AZNNegative Net Change PFENegative Net Change MRKNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
by Ahan Chakraborty
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
AZNNegative Net Change JNJNegative Net Change BDTXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
by Ahan Chakraborty
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
AZNNegative Net Change JNJNegative Net Change BDTXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
by Ahan Chakraborty
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
AZNNegative Net Change JNJNegative Net Change BDTXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Novo Nordisk vs. Amgen: Which Pharma Stock Is the Better Buy?
by Ahan Chakraborty
NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy
by Zacks Equity Research
DYN shares jump after the company files a BLA with the FDA for z-rostudirsen in Duchenne muscular dystrophy.
DYNPositive Net Change LQDANegative Net Change IMCRPositive Net Change INDVNegative Net Change
biotechs
FDA Extends Review Time for AZN's Camizestrant Combo in Breast Cancer
by Zacks Equity Research
AstraZeneca faces a longer FDA review for camizestrant combo in a certain type of first-line breast cancer after regulators request additional data.
AZNNegative Net Change IMCRPositive Net Change DSGNNegative Net Change JSPRNegative Net Change
biotechs medical
Can Asceniv Help ADMA Navigate the Current IG Market Challenges?
by Ekta Bagri
ADMA faces IG pricing pressure and reduced 2026 guidance, but Asceniv demand remains strong amid resilient patient utilization.
GRFSNegative Net Change ADMAPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals